Current Price and Trading Range
As of 12 Aug 2026, Jubilant Pharmova’s stock closed at ₹962.70, marginally up from the previous close of ₹961.70. The day’s trading saw a high of ₹988.90 and a low of ₹911.00, indicating a relatively wide intraday range. The stock remains well below its 52-week high of ₹1,183.90 but comfortably above the 52-week low of ₹783.75, reflecting a moderate recovery from recent lows.
Technical Trend Overview
The overall technical trend has shifted from bearish to mildly bearish, signalling a potential easing of downward pressure. This nuanced change is supported by a mixed set of technical indicators across different time frames.
MACD Analysis
The Moving Average Convergence Divergence (MACD) remains bearish on the weekly chart, indicating that the short-term momentum is still under pressure. However, the monthly MACD has improved to a mildly bearish stance, suggesting that longer-term momentum may be stabilising. This divergence between weekly and monthly MACD readings highlights a transitional phase where short-term weakness could be giving way to a more neutral or cautiously optimistic outlook.
RSI Signals
The Relative Strength Index (RSI) currently shows no clear signal on both weekly and monthly charts. This neutrality implies that the stock is neither overbought nor oversold, which could mean that the price is consolidating and awaiting a catalyst for a decisive move. Investors should watch for any RSI movement beyond the typical 30-70 range to identify potential momentum shifts.
Bollinger Bands and Moving Averages
Bollinger Bands present a bullish signal on the weekly chart, indicating that price volatility may be expanding upwards and that the stock could be poised for a rebound. Contrastingly, the monthly Bollinger Bands remain mildly bearish, reflecting caution over the longer term. Daily moving averages also suggest a mildly bearish trend, reinforcing the idea that while short-term price action shows some strength, the broader trend remains subdued.
Other Technical Indicators
The Know Sure Thing (KST) indicator is mildly bearish on both weekly and monthly time frames, aligning with the overall cautious tone. Dow Theory assessments similarly reflect a mildly bearish stance, indicating that the stock has yet to confirm a sustained uptrend. On-Balance Volume (OBV) readings also remain mildly bearish, suggesting that volume trends have not yet supported a strong price rally.
Rising fast and still accelerating! This Small Cap from FMCG sector is riding pure momentum right now. Jump in before the rally reaches its peak!
- - Accelerating price action
- - Pure momentum play
- - Pre-peak entry opportunity
Comparative Returns and Market Context
Jubilant Pharmova’s recent returns present a mixed picture when compared with the broader Sensex index. Over the past week, the stock outperformed the Sensex with a 3.14% gain versus the benchmark’s 0.35% decline. However, over the last month, the stock’s return of 0.19% lagged behind the Sensex’s 0.75% rise. Year-to-date, Jubilant Pharmova has declined by 10.43%, underperforming the Sensex’s 8.29% fall. Over the last year, the stock’s 12.73% loss is notably worse than the Sensex’s 3.04% decline.
Longer-term performance remains a bright spot, with Jubilant Pharmova delivering a 115.51% return over three years, significantly outpacing the Sensex’s 19.64% gain. Over five and ten years, the stock has also outperformed, returning 44.68% and 255.46% respectively, compared to the Sensex’s 43.33% and 180.53%. This long-term outperformance underscores the company’s underlying growth potential despite recent volatility.
Mojo Score and Ratings Update
MarketsMOJO’s latest assessment assigns Jubilant Pharmova a Mojo Score of 28.0, categorising it as a Strong Sell. This represents a downgrade from the previous Sell rating on 21 Jul 2026, reflecting deteriorating technical and fundamental metrics. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility and risk.
Investor Implications and Outlook
The technical indicators suggest that Jubilant Pharmova is in a phase of cautious consolidation. While some weekly signals such as the Bollinger Bands hint at potential upward momentum, the prevailing mildly bearish readings across key indicators like MACD, KST, and OBV counsel prudence. The absence of a clear RSI signal further emphasises the need for investors to monitor developments closely before committing to a position.
Given the stock’s recent underperformance relative to the Sensex and the downgrade to a Strong Sell rating, investors should weigh the risks carefully. The long-term outperformance offers some comfort, but near-term technicals indicate that the stock may face resistance in breaking out of its current range.
Holding Jubilant Pharmova Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary
Jubilant Pharmova Ltd’s technical landscape is characterised by a subtle shift towards a less bearish outlook, though the majority of indicators remain cautious. The stock’s modest intraday gains and weekly bullish Bollinger Bands offer some optimism, but the broader mildly bearish signals across MACD, KST, Dow Theory, and OBV suggest that investors should remain vigilant. The company’s downgrade to a Strong Sell rating by MarketsMOJO further underscores the need for careful analysis before initiating or increasing exposure.
Long-term investors may find comfort in the stock’s impressive multi-year returns, but short- to medium-term traders should watch for confirmation of momentum shifts, particularly through RSI breakouts or sustained MACD improvements. Until then, Jubilant Pharmova appears to be navigating a complex technical environment with mixed signals that warrant a balanced and measured approach.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
